Ferrer’s constant commitment to innovation means that a strategy of alliances and collaboration with public research bodies and prestigious biotech companies is essential.

Ferrer - CNIC

The Spanish National Centre for Cardiovascular Research (CNIC) is a public institution connected to the Carlos III Health Institute, which, under the leadership of its General Director, the distinguished cardiologist Dr. Valentin Fuster, has become a leading international research organization. Its mission is to undertake research into cardiovascular diseases with the aim of translating its expertise into clinical excellence, in order to prioritise prevention and promote health.

The CNIC and Ferrer, with the backing of the World Heart Federation, has developed the world’s first polypill for the secondary prevention of cardiovascular accidents in patients already undergoing treatment. It presents an important galenic innovation which ensures the stability and non-interaction of its three components.

It represents a significant advance in the worldwide treatment of cardiovascular diseases. The objective is to reduce the risk of suffering a second cardiovascular event. It provides medical professionals with a new therapeutic alternative, of proven efficacy, to improve patient adherence. Furthermore, ensuring affordable patient access to the treatment is one of the pillars of the CNIC-Ferrer project.

Ferrer - Alexza

Alexza is a pharmaceutical company based in the United States dedicated to the research, development and commercialization of novel proprietary products for the treatment of acute and intermittent conditions.

The company's innovative products are based on the proprietary Staccato® system, an inhaler which vaporizes excipient-free drugs, achieving pharmacokinetic properties similar to intravenous administration and rapid systemic effects.

Adasuve® is designed for the rapid treatment of mild to moderate agitation in adults with schizophrenia or bipolar disorder, by combining the Staccato system with loxapine, an antipsychotic drug currently available in various formulations.


Our aim is to establish long-term relationships with biotechnology and biopharmaceutical companies in our strategic therapeutic areas.